• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用喷雾干燥法和 SAS 工艺制备无定形头孢地尼及其药物特征研究。

Preparation and pharmaceutical characterization of amorphous cefdinir using spray-drying and SAS-process.

机构信息

Center for Nanotechnology-based New Drug Dosage Form, College of Pharmacy, Chungnam National University, 220 Gung-dong, Yuseung-gu, Daejeon 305-764, Republic of Korea.

出版信息

Int J Pharm. 2010 Aug 30;396(1-2):239-45. doi: 10.1016/j.ijpharm.2010.06.032. Epub 2010 Jun 25.

DOI:10.1016/j.ijpharm.2010.06.032
PMID:20599602
Abstract

The aim of this study was to investigate the effects of micronization and amorphorization of cefdinir on solubility and dissolution rate. The amorphous samples were prepared by spray-drying (SD) and supercritical anti-solvent (SAS) process, respectively and their amorphous natures were confirmed by DSC, PXRD and FT-IR. Thermal gravimetric analysis was performed by TGA. SEM was used to investigate the morphology of particles and the processed particle had a spherical shape, while the unprocessed crystalline particle had a needle-like shape. The mean particle size and specific surface area were measured by dynamic light scattering (DLS) and BET, respectively. The DLS result showed that the SAS-processed particle was the smallest, followed by SD and the unprocessed cefdinir. The BET result was the same as DLS result in that the SAS-processed particle had the largest surface area. Therefore, the processed cefdinir, especially the SAS-processed particle, appeared to have enhanced apparent solubility, improved intrinsic dissolution rate and better drug release when compared with SD-processed and unprocessed crystalline cefdinir due not only to its amorphous nature, but also its reduced particle size. Conclusions were that the solubility and dissolution rate of crystalline cefdinir could be improved by physically modifying the particles using SD and SAS-process. Furthermore, SAS-process was a powerful methodology for improving the solubility and dissolution rate of cefdinir.

摘要

本研究旨在探讨头孢地尼的微粉化和非晶化对其溶解度和溶出速率的影响。采用喷雾干燥(SD)和超临界抗溶剂(SAS)法分别制备了无定形样品,并通过差示扫描量热法(DSC)、粉末 X 射线衍射(PXRD)和傅里叶变换红外光谱(FT-IR)确认了其无定形性质。热重分析(TGA)通过 TGA 进行。扫描电子显微镜(SEM)用于研究颗粒的形态,处理后的颗粒呈球形,而未经处理的结晶颗粒呈针状。通过动态光散射(DLS)和 BET 分别测量了平均粒径和比表面积。DLS 结果表明,SAS 处理后的颗粒最小,其次是 SD 和未经处理的头孢地尼。BET 结果与 DLS 结果相同,即 SAS 处理后的颗粒具有最大的表面积。因此,与 SD 处理和未经处理的结晶头孢地尼相比,处理后的头孢地尼,特别是 SAS 处理后的颗粒,由于其无定形性质和减小的粒径,表现出增强的表观溶解度、提高的内在溶出速率和更好的药物释放。结论是,通过使用 SD 和 SAS 工艺对颗粒进行物理改性,可以提高结晶头孢地尼的溶解度和溶出速率。此外,SAS 工艺是提高头孢地尼溶解度和溶出速率的有效方法。

相似文献

1
Preparation and pharmaceutical characterization of amorphous cefdinir using spray-drying and SAS-process.采用喷雾干燥法和 SAS 工艺制备无定形头孢地尼及其药物特征研究。
Int J Pharm. 2010 Aug 30;396(1-2):239-45. doi: 10.1016/j.ijpharm.2010.06.032. Epub 2010 Jun 25.
2
Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.采用超临界抗溶剂(SAS)法制备、表征及体内评价无定形阿托伐他汀钙纳米粒
Eur J Pharm Biopharm. 2008 Jun;69(2):454-65. doi: 10.1016/j.ejpb.2008.01.007. Epub 2008 Jan 18.
3
Preparation, characterization and in vivo assessment of the bioavailability of glycyrrhizic acid microparticles by supercritical anti-solvent process.超临界抗溶剂法制备、表征及体内评价甘草酸微球的生物利用度。
Int J Pharm. 2012 Feb 28;423(2):471-9. doi: 10.1016/j.ijpharm.2011.12.007. Epub 2011 Dec 13.
4
Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process.采用喷雾干燥法和超临界抗溶剂沉淀法制备的非晶态阿托伐他汀半钙盐的理化性质及口服生物利用度
Int J Pharm. 2008 Jul 9;359(1-2):211-9. doi: 10.1016/j.ijpharm.2008.04.006. Epub 2008 Apr 12.
5
Comparative physicochemical characterization of phospholipids complex of puerarin formulated by conventional and supercritical methods.采用常规方法和超临界方法制备的葛根素磷脂复合物的比较理化特性
Pharm Res. 2008 Mar;25(3):563-77. doi: 10.1007/s11095-007-9418-x. Epub 2007 Sep 8.
6
Enhanced dissolution of megestrol acetate microcrystals prepared by antisolvent precipitation process using hydrophilic additives.使用亲水性添加剂的抗溶剂沉淀法制备醋酸甲地孕酮微晶的增溶作用。
Int J Pharm. 2010 Aug 30;396(1-2):91-8. doi: 10.1016/j.ijpharm.2010.06.016. Epub 2010 Jun 15.
7
Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus.固体分散体法对他克莫司溶解度和结晶性质的影响。
Int J Pharm. 2010 Aug 16;395(1-2):161-6. doi: 10.1016/j.ijpharm.2010.05.023. Epub 2010 May 24.
8
Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.吲哚美辛/PVP固体分散体肠溶微粒的拉曼光谱与热分析
Eur J Pharm Biopharm. 2008 Sep;70(1):409-20. doi: 10.1016/j.ejpb.2008.03.016. Epub 2008 Apr 8.
9
Formation of bicalutamide nanodispersion for dissolution rate enhancement.形成比卡鲁胺纳米分散体以提高溶解速率。
Int J Pharm. 2011 Feb 14;404(1-2):257-63. doi: 10.1016/j.ijpharm.2010.11.015. Epub 2010 Nov 18.
10
Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.采用超临界抗溶剂(SAS)法制备辛伐他汀/羟丙基-β-环糊精包合物及其表征
Eur J Pharm Biopharm. 2007 Jun;66(3):413-21. doi: 10.1016/j.ejpb.2006.11.013. Epub 2006 Nov 29.

引用本文的文献

1
An emerging terpolymeric nanoparticle pore former as an internal recrystallization inhibitor of celecoxib in controlled release amorphous solid dispersion beads: Experimental studies and molecular dynamics analysis.一种新型三元共聚物纳米颗粒成孔剂作为塞来昔布在控释无定形固体分散体微丸中的内部重结晶抑制剂:实验研究与分子动力学分析
Acta Pharm Sin B. 2024 Jun;14(6):2669-2684. doi: 10.1016/j.apsb.2024.03.026. Epub 2024 Mar 22.
2
Synthesis of Celecoxib-Eutectic Mixture Particles via Supercritical CO Process and Celecoxib Immediate Release Tablet Formulation by Quality by Design Approach.通过超临界CO₂ 工艺合成塞来昔布共晶混合物颗粒及采用质量源于设计方法制备塞来昔布速释片
Pharmaceutics. 2022 Jul 26;14(8):1549. doi: 10.3390/pharmaceutics14081549.
3
Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies.药物非晶态固体分散体:制备策略综述
Acta Pharm Sin B. 2021 Aug;11(8):2505-2536. doi: 10.1016/j.apsb.2021.05.014. Epub 2021 Jun 5.
4
Co-Amorphous Solid Dispersions for Solubility and Absorption Improvement of Drugs: Composition, Preparation, Characterization and Formulations for Oral Delivery.用于改善药物溶解度和吸收的共无定形固体分散体:组成、制备、表征及口服给药制剂
Pharmaceutics. 2018 Jul 19;10(3):98. doi: 10.3390/pharmaceutics10030098.
5
Influence of Solvent Composition on the Performance of Spray-Dried Co-Amorphous Formulations.溶剂组成对喷雾干燥共无定形制剂性能的影响
Pharmaceutics. 2018 Apr 12;10(2):47. doi: 10.3390/pharmaceutics10020047.